Transaction details
Director Christopher Causey of United Therapeutics (NASDAQ: UTHR) executed a sale of 20 shares of the company's common stock on March 4, 2026. The shares were sold at an average price of $490.1685, resulting in total proceeds of $9,803. Reported trade prices for the block ranged narrowly between $490.12 and $490.21.
On the same date, Causey also exercised stock options to acquire an additional 20 shares of United Therapeutics common stock at an exercise price of $119.76 per share, for a total outlay of $2,395. Following these moves, Causey is reported to directly own 4,190 shares of United Therapeutics.
The filings indicate both the sale and the option exercise were executed under a pre-arranged Rule 10b5-1 trading plan.
Market context and valuation
The insider activity occurred as the shares were trading near InvestingPro's Fair Value estimate. Over the past 12 months, United Therapeutics shares have returned 58%.
Analyst commentary and clinical news
Following recent developments at the company, several brokerages updated their price targets while leaving buy ratings intact. UBS raised its price target for United Therapeutics to $705 from $655 while maintaining a Buy rating and citing multiple catalysts expected in the near-to-medium term. Jefferies increased its target to $668 from $640 and likewise kept a Buy rating, referencing positive Phase 3 results for ralinepag, a pulmonary arterial hypertension treatment. The Phase 3 trial met its primary endpoint, showing a 55% reduction in the risk of clinical worsening. TD Cowen reiterated a Buy rating and a $575 price target, highlighting the trial's 55% reduction in clinical worsening observed in a heavily pre-treated patient population. These analyst updates reflect a positive reception to the ralinepag data and related potential developments.
Research access
Investors seeking more detailed analysis of United Therapeutics' valuation or patterns in executive trading can consult the comprehensive Pro Research Report, which is available for this and 1,400+ other U.S. equities on InvestingPro.
Notes
The article reports the transactions, the subsequent share ownership figure for Causey, and the analyst reactions as disclosed. No additional inference about motives or future stock performance is provided beyond the documented facts and analyst statements cited above.